|
1.
|
|
14 p, 1.4 MB |
Hsa-miR-155-5p Up-Regulation in Breast Cancer and Its Relevance for Treatment With Poly[ADP-Ribose] Polymerase 1 (PARP-1) Inhibitors
/
Pasculli, B. (Fondazione IRCCS Casa Sollievo Della Sofferenza. Laboratorio di Oncologia) ;
Barbano, R. (Fondazione IRCCS Casa Sollievo Della Sofferenza. Laboratorio di Oncologia) ;
Fontana, A. (Fondazione IRCCS Casa Sollievo Della Sofferenza) ;
Biagini, T. (Fondazione IRCCS Casa Sollievo Della Sofferenza. Laboratory of Bioinformatics Unit) ;
Di Viesti, M.P. (Department of Medicine. Scuola Medica Salernitana," University of Salerno) ;
Rendina, M. (Fondazione IRCCS Casa Sollievo Della Sofferenza. Laboratorio di Oncologia) ;
Valori, V.M. (Fondazione IRCCS Casa Sollievo Della Sofferenza. UO di Oncologia. San Giovanni Rotondo) ;
Morritti, M. (Fondazione IRCCS Casa Sollievo Della Sofferenza. UO di Oncologia. San Giovanni Rotondo) ;
Bravaccini, S. (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS. Biosciences Laboratory) ;
Ravaioli, S. (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS. Biosciences Laboratory) ;
Maiello, E. (Fondazione IRCCS Casa Sollievo Della Sofferenza. UO di Oncologia. San Giovanni Rotondo) ;
Graziano, P. (Fondazione IRCCS Casa Sollievo Della Sofferenza) ;
Murgo, R. (Fondazione IRCCS Casa Sollievo Della Sofferenza) ;
Copetti, M. (Fondazione IRCCS Casa Sollievo Della Sofferenza) ;
Mazza, T. (Fondazione IRCCS Casa Sollievo Della Sofferenza. Laboratory of Bioinformatics Unit) ;
Fazio, V.M. (Fondazione IRCCS Casa Sollievo Della Sofferenza. Laboratorio di Oncologia) ;
Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Parrella, P. (Fondazione IRCCS Casa Sollievo Della Sofferenza. Laboratorio di Oncologia) ;
Universitat Autònoma de Barcelona
miR-155-5p is a well-known oncogenic microRNA, showing frequent overexpression in human malignancies, including breast cancer. Here, we show that high miR-155-5p levels are associated with unfavorable prognostic factors in two independent breast cancer cohorts (CSS cohort, n = 283; and TCGA-BRCA dataset, n = 1,095). [...]
2020 -  10.3389/fonc.2020.01415
Frontiers in Oncology, Vol. 10 (december 2020) , p. 1415
|
|
|
2.
|
|
11 p, 1.2 MB |
Up-regulation of HDACs, a harbinger of uraemic endothelial dysfunction, is prevented by defibrotide
/
Palomo, Marta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Vera, Manuel (Nephrology Department. Hospital Clinic. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). Universitat de Barcelona (UB)) ;
Martin, S. (Hematopathology. Centre Diagnòstic Biomèdic (CDB). Hospital Clinic. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). Universitat de Barcelona (UB)) ;
Torramadé-Moix, S. (Hematopathology. Centre Diagnòstic Biomèdic (CDB). Hospital Clinic. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). Universitat de Barcelona (UB)) ;
Martinez-Sanchez, Julia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Belen Moreno, A. (Hematopathology. Centre Diagnòstic Biomèdic (CDB). Hospital Clinic. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). Universitat de Barcelona (UB)) ;
Carreras, Enric (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Escolar, G. (Hematopathology. Centre Diagnòstic Biomèdic (CDB). Hospital Clinic. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). Universitat de Barcelona (UB)) ;
Cases, A. (Nephrology Department. Hospital Clinic. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). Universitat de Barcelona (UB)) ;
Díaz-Ricart, M. (Barcelona Endothelium Team (BET)) ;
Universitat Autònoma de Barcelona
Endothelial dysfunction is an earlier contributor to the development of atherosclerosis in chronic kidney disease (CKD), in which the role of epigenetic triggers cannot be ruled out. Endothelial protective strategies, such as defibrotide (DF), may be useful in this scenario. [...]
2020 - 10.1111/jcmm.14865
Journal of Cellular and Molecular Medicine, Vol. 24 Núm. 2 (january 2020) , p. 1713-1723
|
|
|
3.
|
|
16 p, 704.6 KB |
Hasta que los astros se alineen : espacios, cuerpos y tecnología en la trilogía de Claudia Aboaf
/
Pérez Gras, María Laura (Universidad de Buenos Aires)
Identificamos dos nuevas tendencias de la última década en la narrativa especulativa argentina: una mayor visibilidad de la escritura de mujeres dentro de la creciente presencia de la ciencia ficción en el país y una apertura temática a los problemas ecológicos. [...]
We identify two new trends of the last decade in Argentine speculative narrative: a greater visibility of women's writing within the growing presence of science fiction in the country and a thematic openness to ecological problems. [...]
Identifiquem dues noves tendències de la darrera dècada en la narrativa especulativa argentina: una major visibilitat de l'escriptura de dones dins de la creixent presència de la ciència-ficció al país i una obertura temàtica als problemes ecològics. [...]
2020 - 10.5565/rev/mitologias.747
Mitologías hoy, Vol. 22 (2020) , p. 175-190 (Dossier)
|
|
|
4.
|
|
15 p, 2.5 MB |
Follow-up of late-onset Pompe disease patients with muscle magnetic resonance imaging reveals increase in fat replacement in skeletal muscles
/
Nuñez-Peralta, Claudia (Institut d'Investigació Biomèdica Sant Pau) ;
Alonso-Pérez, Jorge (Institut d'Investigació Biomèdica Sant Pau) ;
Llauger, Jaume (Institut d'Investigació Biomèdica Sant Pau) ;
Segovia, Sonia (Institut d'Investigació Biomèdica Sant Pau) ;
Montesinos, Paula (Philips Healthcare Iberia) ;
Belmonte, Izaskun (Institut d'Investigació Biomèdica Sant Pau) ;
Pedrosa, Irene (Institut d'Investigació Biomèdica Sant Pau) ;
Montiel, Elena (Institut d'Investigació Biomèdica Sant Pau) ;
Alonso-Jiménez, Alicia (Institut d'Investigació Biomèdica Sant Pau) ;
Sánchez-González, Javier (Philips Healthcare Iberia) ;
Martínez-Noguera, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Illa, Isabel (Institut d'Investigació Biomèdica Sant Pau) ;
Diaz-Manera, Jordi (University of Newcastle) ;
Universitat Autònoma de Barcelona
Late-onset Pompe disease (LOPD) is a genetic disorder characterized by progressive degeneration of the skeletal muscles produced by a deficiency of the enzyme acid alpha-glucosidase. Enzymatic replacement therapy with recombinant human alpha-glucosidase seems to reduce the progression of the disease; although at the moment, it is not completely clear to what extent. [...]
2020 - 10.1002/jcsm.12555
Journal of Cachexia, Sarcopenia and Muscle, Vol. 11 (march 2020) , p. 1032-1046
|
|
|
5.
|
|
9 p, 1.0 MB |
Behavior of hyperreflective foci in non-infectious uveitic macular edema, a 12-month follow-up prospective study
/
Berasategui, Barbara (Instituto de Investigación Sanitaria Biocruces Bizkaia) ;
Fonollosa, Alex (Instituto de Investigación Sanitaria Biocruces Bizkaia) ;
Artaraz, Joseba (Instituto de Investigación Sanitaria Biocruces Bizkaia) ;
Ruiz Arruza, Ioana (Instituto de Investigación Sanitaria Biocruces Bizkaia) ;
Ríos, Jose (Universitat Autònoma de Barcelona. Unitat de Bioestadística) ;
Matas, Jessica (Hospital Clínic i Provincial de Barcelona) ;
Llorenç, Victor (Hospital Clínic i Provincial de Barcelona) ;
Diaz Valle, David (Hospital Clínico San Carlos) ;
Sastre Ibañez, Marina (Hospital Clínico San Carlos) ;
Arriola Villalobos, Pedro (Hospital Clínico San Carlos) ;
Adan, Alfredo (Hospital Clínic i Provincial de Barcelona)
Hyperreflective foci have been described in OCT imaging of patients with retinal vascular diseases. It has been suggested that they may play a role as a prognostic factor of visual outcomes in these diseases. [...]
2018 - 10.1186/s12886-018-0848-5
BMC Ophthalmology, Vol. 18 (july 2018)
|
|
|
6.
|
|
15 p, 1.0 MB |
An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer
/
Soria, Francesco (Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy) ;
Droller, Michael J. (The Mount Sinai Medical Center. Department of Urology) ;
Lotan, Yair (University of Texas Southwestern Medical Center. Department of Urology) ;
Gontero, Paolo (Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy) ;
D'Andrea, David (Medical University of Vienna. Department of Urology and Comprehensive Cancer Center, Vienna General Hospital) ;
Gust, Kilian M. (Medical University of Vienna. Department of Urology and Comprehensive Cancer Center, Vienna General Hospital) ;
Rouprêt, Morgan (Assistance Publique-Hôpitaux de Paris Sorbonne Université. Department of Urology, Hôpital Pitié-Salpétrière) ;
Babjuk, Marek (Medical University of Vienna. Department of Urology and Comprehensive Cancer Center, Vienna General Hospital) ;
Palou, Joan (Institut d'Investigació Biomèdica Sant Pau) ;
Shariat, Shahrokh F. (Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria) ;
Universitat Autònoma de Barcelona
With the advent of novel genomic and transcriptomic technologies, new urinary biomarkers have been identified and tested for bladder cancer (BCa) surveillance. To summarize the current status of urinary biomarkers for the detection of recurrence and/or progression in the follow-up of non-muscle invasive BCa patients, and to assess the value of urinary biomarkers in predicting response to intravesical Bacillus Calmette-Guerin (BCG) therapy. [...]
2018 - 10.1007/s00345-018-2380-x
World Journal of Urology, Vol. 36 (june 2018) , p. 1981-1995
|
|
|
7.
|
|
18 p, 504.6 KB |
Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis : Results from Greater Than 17,000 Patient-Years of Exposure
/
Armstrong, April (Keck School of Medicine of the University of Southern California. Department of Clinical Research) ;
Paul, Carle (Paul Sabatier University. Dermatology Department, Toulouse University Hospital (CHU)) ;
Puig, Luis (Institut d'Investigació Biomèdica Sant Pau) ;
Boehncke, Wolf Henning (University of Geneva. Department of Pathology and Immunology) ;
Freeman, Michael (The Skin Centre, Benowa, QLD Australia) ;
Torii, Hideshi (Tokyo Yamate Medical Center. Division of Dermatology) ;
Papp, Kim (K Papp Clinical Research and Probity Medical Research) ;
Griffiths, Christopher E. M. (NIHR Manchester Biomedical Research Centre. Dermatology Centre, Salford Royal Hospital, University of Manchester) ;
Blauvelt, Andrew (Oregon Medical Research Center) ;
Reich, Kristian (Skinflammation® Center, Hamburg, Germany) ;
Gooderham, Melinda (Centre for Dermatology and Probity Medical Research, Peterborough, ON Canada) ;
Terui, Tadashi (Nihon University School of Medicine. Department of Dermatology) ;
Renda, Lisa (Eli Lilly and Company) ;
Agada, Noah (Eli Lilly and Company) ;
Xu, Wen (Eli Lilly and Company) ;
Gallo, Gaia (Eli Lilly and Company) ;
Lebwohl, Mark G. (Icahn School of Medicine at Mount Sinai. Department of Dermatology) ;
Universitat Autònoma de Barcelona
Long-term safety data are critical for evaluating therapies for psoriasis. Ixekizumab has demonstrated efficacy and is well tolerated for the treatment of moderate-to-severe plaque psoriasis. We examined the safety and tolerability of up to 5 years of ixekizumab therapy in patients with psoriasis. [...]
2019 - 10.1007/s13555-019-00340-3
Dermatology and Therapy, Vol. 10 (november 2019) , p. 133-150
|
|
|
8.
|
|
12 p, 1.8 MB |
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL : 5 years of follow-up from the phase 3 RESONATE-2 study
/
Burger, Jan A. (University of Texas MD Anderson Cancer Center. Department of Leukemia) ;
Barr, Paul M. (Wilmot Cancer Institute, University of Rochester Medical Center) ;
Robak, Tadeusz (Medical University of Lodz, Copernicus Memorial Hospital) ;
Owen, Carolyn (University of Calgary. Tom Baker Cancer Centre) ;
Ghia, P (Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy) ;
Bairey, Osnat (Tel Aviv University. Rabin Medical Center, Petah Tikva, Israel and Sackler Faculty of Medicine) ;
Hillmen, Peter (University of Leeds. The Leeds Teaching Hospitals, St. James Institute of Oncology) ;
Coutre, Steven E. (Stanford University School of Medicine. Stanford Cancer Center) ;
Devereux, Stephen (NHS Foundation Trust. Kings College Hospital) ;
Grosicki, Sebastian (Silesiam Medical University. Department of Hematology and Cancer Prevention) ;
McCarthy, Helen (Royal Bournemouth General Hospital) ;
Simpson, David (North Shore Hospital) ;
Offner, Fritz (Universitair Ziekenhuis Gent) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Dai, Sandra (Pharmacyclics LLC, an AbbVie Company) ;
Lal, Indu (Pharmacyclics LLC, an AbbVie Company) ;
Dean, James P. (Pharmacyclics LLC, an AbbVie Company) ;
Kipps, Thomas J. (UCSD Moores Cancer Center) ;
Universitat Autònoma de Barcelona
RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or chlorambucil 0. [...]
2019 - 10.1038/s41375-019-0602-x
Leukemia, Vol. 34 (october 2019) , p. 787-798
|
|
|
9.
|
|
9 p, 1.6 MB |
Biplane opening wedge high tibial osteotomy with a distal tuberosity osteotomy, radiological and clinical analysis with minimum follow-up of 2 years
/
Erquicia, Juan (ICATME, Hospital Universitari Dexeus, UAB) ;
Gelber Ghertner, Pablo Eduardo (Institut d'Investigació Biomèdica Sant Pau) ;
Perelli, Simone (Hospital Universitari Quirón Dexeus - UAB) ;
Ibañez, Federico (Hospital Universitari Quirón Dexeus - UAB) ;
Ibañez, Maximiliano (Hospital Universitari Quirón Dexeus - UAB) ;
Pelfort, Xavier (Department of Orthopaedic Surgery, Consorci Sanitari de l'Anoia, Hospital de Igualada, Av. Catalunya, 11, Barcelona, Spain) ;
Monllau, Juan Carlos (Hospital del Mar (Barcelona)) ;
Universitat Autònoma de Barcelona
High tibial osteotomy is an established and helpful treatment for unicompatimental osteoarthritis associated with varus deformity. However, asupratubercle high tibial osteotomy leads to a decrease in patellar height making the technique not suitable in case of concomitant patella baja. [...]
2019 - 10.1186/s40634-019-0176-6
Journal of Experimental Orthopaedics, Vol. 6 (february 2019)
|
|
|
10.
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
